Evidence map›Paper›PMID 40044047›Full record

ArticleOphthalmology2025

Early Postoperative Conjunctival Complications Leading to Exposure of Surgically Implanted CorNeat EverPatch Devices.

Jacob Kanter, Atul Garkal, Nur Cardakli, Ian Pitha, Jasdeep Sabharwal, Oliver D Schein, Pradeep Y Ramulu, Kunal S Parikh, Thomas V Johnson

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Netarsudil-associated conjunctival fragility.American journal of ophthalmology case reports · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jacob KanterGlaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Atul GarkalGlaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Center for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Nur CardakliGlaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Ian PithaMoran Eye Center, University of Utah, Salt Lake City, Utah.
Jasdeep SabharwalNorth Bay Eye Associates, Petaluma, California.
Oliver D ScheinCornea Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Pradeep Y RamuluGlaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Kunal S ParikhGlaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Center for Nanomedicine, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Center for Bioengineering Innovation & Design, Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Thomas V JohnsonGlaucoma Center of Excellence, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland; Cellular and Molecular Medicine Program, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: johnson@jhmi.edu.

Funding

Wilmer Core Grant for Vision ResearchP30EY001765 · NEI · JOHNS HOPKINS UNIVERSITY · PI Ji Yi · 1985 to 2026
$22.1M
Understanding and optimizing the influence of glaucoma drainage implant surface architecture and design to prevent post-operative fibrosisR01EY035669 · NEI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Kunal Sailesh Parikh, Ian Franz Pitha · 2024 to 2026
$1.2M
Transplantation of human stem cell-derived neurons for retinal ganglion cell replacement and optic nerve regeneration.K08EY031801 · NEI · JOHNS HOPKINS UNIVERSITY · PI JOHNSON, THOMAS VINCENT · 2020 to 2024
$945k
NEI NIH HHS K08 EY031801NEI NIH HHS P30 EY001765NEI NIH HHS R01 EY035669
6 · The paper itself

Abstract

purposeTo compare the early exposure and surgical revision rates between a new synthetic tissue substitute (CorNeat EverPatch) with that of human donor cornea after placement onto the scleral surface during ophthalmic surgery and study the biomaterial properties of the synthetic patch material.

designRetrospective comparison study and biomaterial analyses of new and explanted synthetic patch material.

participantsAll consecutive patients who underwent ophthalmic surgery with implantation of the CorNeat EverPatch at the Wilmer Eye Institute (occurring from February through August 2024) and a comparison group who underwent ophthalmic surgery with implantation of irradiated donor cornea, matched 1:2 with patients receiving EverPatch for age, type of glaucoma, and surgeon.

methodsRetrospective review of clinical electronic medical records of patients who underwent surgery at the Wilmer Eye Institute. Materials characterization of EverPatch, including morphologic features, surface roughness, wettability, thermal stability, elemental analysis, and physical properties.

main outcome measuresEarly exposure (within 5 months of surgery) and surgical revision rates after CorNeat EverPatch or irradiated human donor cornea implantation during ophthalmic surgery.

resultsThirty patients undergoing ophthalmic surgery in 2024 received EverPatch implantation during primary tube shunt placement (n = 27), tube shunt revision (n = 2), or covering of exposed suture used for scleral fixation of an intraocular lens (n = 1). During the early postoperative period, the rate of EverPatch exposure was 48.3% and the rate of surgical revision was 27.9%. In case-matched control participants (n = 58), the rate of patch graft exposure was 1.7% (P < 0.0001) and the rate of surgical revision was 1.7% (P < 0.0001). EverPatch devices constituted a randomly aligned fibrous mesh with an average fiber diameter of 1.36 ± 0.78 μm, surface roughness of 1.3 ± 0.1 μm, pore size of 3.7 ± 0.4 μm

conclusionsThe rate of early conjunctival complications leading to exposure of the CorNeat EverPatch was higher than that of irradiated human donor corneal patch grafts. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

ConjunctivaConjunctival DiseasesCorneaCorneal TransplantationGlaucomaGlaucoma Drainage ImplantsPostoperative ComplicationsProstheses and ImplantsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedProsthesis ImplantationconjunctivaElectrospinningGlaucoma surgeryPatch graftTube shunt

Identifiers

PMID40044047
PMCPMC12182999

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.